42.78 -1.98 (-4.60%)
BIIB
Stock Details
Last Trade:42.78 Change:-1.98 (-4.60%) Prev Close:44.76 Open: 43.08 Days Range:40.39 – 45.98 52 Week Range: 44.66 - 84.75 Volume:8277729 P/E: 18.60EPS:2.30
View AllRecent Alerts 10/11/08
Recent Alert on 10/10/08 at 9:35am
Morning Movers 10/10: Morgan Stanley (MS) Slammed Again on Liquidity Fears, Moody's Downgrade; Wachovia (WB) Up
Morning Movers 10/10: Morgan Stanley (MS) Slammed Again on Liquidity Fears, Moody's Downgrade; Wachovia (WB) Up
StreetInsider.com Morning Movers: Morgan Stanley (NYSE: MS) 29% LOWER; Moody's places on review for downgrade. Concerns about liquidity. Imation Corp. (NYSE: IMN) 22% LOWER; sees Q3 revenue of approximately $525 million, below the consensus... Read More
Recent Alert on 10/09/08 at 5:52pm
After-Hours Movers 10/09: Wachovia (WB) Up After No Deal Reached Between Citi and Wells Fargo; Imation (IMN) Sinks On Guidance
After-Hours Movers 10/09: Wachovia (WB) Up After No Deal Reached Between Citi and Wells Fargo; Imation (IMN) Sinks On Guidance
Recent Alert on 10/09/08 at 4:04pm
Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Recent Alert on 10/09/08 at 4:04pm
Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Recent Alert on 10/07/08 at 7:44am
Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
View AllRecent Press Releases
Press Release on 10/09/08 at 4:00pm
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
View AllRecent SEC Filings
No Recent SEC Filings Available